why choose us

First received: November 14, 2022

Clinical Trial: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acneiform Eruption Due to Chemical

Study Type: INTERVENTIONAL


Official Title: A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epid

Brief Summary: The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities.The main questions it aims to answer are:Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale [ARIGA]Evaluate the safety of HT-001 during treatmentParticipants will apply HT-001 Gel once per day for 6 weeks, during which…

Read more